ResMed General Counsel Sells Shares Under Pre-Set Trading Plan

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an update.

ResMed’s Global General Counsel and Secretary, Michael J. Rider, reported the sale of 50 shares of ResMed common stock at a price of $260.00 per share, leaving him with beneficial ownership of 9,691 shares. The transaction, dated 4 February 2026, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 28 February 2025, indicating a scheduled personal portfolio adjustment rather than a discretionary sale, with limited direct impact on the company’s operations or strategic positioning.

Such insider transactions are closely watched by investors for signals about executive confidence, though the relatively small size of this sale suggests it is unlikely to materially affect market perception of ResMed’s outlook. The filing underscores ongoing adherence to U.S. securities regulations and structured compliance practices around insider trading, providing transparency for shareholders and regulators regarding executive equity activity.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a medical technology company that develops and manufactures devices and software for the treatment of sleep-disordered breathing and other chronic respiratory conditions. The company focuses on sleep apnea therapy and cloud-connected solutions for patients and healthcare providers in global markets, including the U.S. and other major healthcare systems.

Average Trading Volume: 1,047,790

Technical Sentiment Signal: Buy

Current Market Cap: A$56.42B

See more insights into RMD stock on TipRanks’ Stock Analysis page.